American Century Companies Inc. Grows Stock Position in Entrada Therapeutics, Inc. $TRDA

American Century Companies Inc. lifted its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 13.5% during the 1st quarter, Holdings Channel reports. The institutional investor owned 67,793 shares of the company’s stock after buying an additional 8,083 shares during the period. American Century Companies Inc.’s holdings in Entrada Therapeutics were worth $613,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of TRDA. BNP Paribas Financial Markets purchased a new position in Entrada Therapeutics in the 4th quarter worth approximately $57,000. State of Wyoming purchased a new position in shares of Entrada Therapeutics in the fourth quarter worth $104,000. Harbor Capital Advisors Inc. purchased a new position in shares of Entrada Therapeutics in the first quarter worth $121,000. Mackenzie Financial Corp purchased a new position in shares of Entrada Therapeutics in the fourth quarter worth $251,000. Finally, Invesco Ltd. increased its stake in shares of Entrada Therapeutics by 45.1% in the first quarter. Invesco Ltd. now owns 16,691 shares of the company’s stock worth $151,000 after buying an additional 5,187 shares during the period. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on TRDA shares. Wall Street Zen cut shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Tuesday, May 20th. Finally, Zacks Research upgraded Entrada Therapeutics to a “hold” rating in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Entrada Therapeutics presently has an average rating of “Buy” and a consensus target price of $25.67.

Entrada Therapeutics Price Performance

Shares of NASDAQ TRDA opened at $5.29 on Friday. Entrada Therapeutics, Inc. has a 1 year low of $4.93 and a 1 year high of $21.79. The company’s 50-day moving average is $6.06 and its 200 day moving average is $7.96. The stock has a market capitalization of $201.23 million, a P/E ratio of -2.97 and a beta of -0.13.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.18). Entrada Therapeutics had a negative net margin of 92.30% and a negative return on equity of 17.81%. The company had revenue of $1.98 million for the quarter, compared to analysts’ expectations of $8.17 million. Research analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Insider Buying and Selling at Entrada Therapeutics

In other news, Director Kush Parmar sold 27,000 shares of the company’s stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $7.50, for a total value of $202,500.00. Following the sale, the director directly owned 1,093,313 shares of the company’s stock, valued at $8,199,847.50. This represents a 2.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Ventures V. L.P. 5Am sold 6,935 shares of the company’s stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total transaction of $52,012.50. Following the completion of the sale, the insider directly owned 1,093,313 shares in the company, valued at $8,199,847.50. This represents a 0.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 254,000 shares of company stock worth $1,782,000. 8.11% of the stock is owned by insiders.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.